No Data
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Cuts Target Price to $30
Crispr Therapeutics Price Target Lowered to $30 From $45 at Morgan Stanley
CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Are up 7.1% This Past Week, but Still in the Red Over the Last Year
Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know